17:46 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived metastatic neuroendocrine prostate cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by culturing enzyme-dissociated cells from samples of a patient’s liver, lymph node...
22:54 , Jan 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Cell culture and mouse studies suggest dual inhibition of AURKA and JAK-2 could help treat GvHD. In co-cultures of human dendritic cells and allogeneic human T cells, a dual inhibitor of...
02:02 , Jan 14, 2017 |  BioCentury  |  Strategy

Solidifying Takeda’s position

Takeda Pharmaceutical Co. Ltd. ’s proposed acquisition of Ariad Pharmaceuticals Inc. should be the boost the pharma needs to hit $10 billion in cancer sales by 2025, as the biotech’s brigatinib is expected to lead...
07:00 , May 30, 2016 |  BioCentury  |  Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into...
08:00 , Dec 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Aurora kinase A (AURKA; Aurora-A)

Transplant INDICATION: Graft-versus-host disease (GvHD) Patient sample and mouse studies suggest that AURKA inhibitors could help treat GvHD following hematopoietic cell transplant (HCT). Levels of AURKA were higher in T cells from HCT patients who...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Aurora kinase A (AURKA; Aurora-A)

Hematology INDICATION: Myeloproliferative disorder Mouse studies suggest AURKA inhibitors could help treat primary myelofibrosis (PMF). Levels of AURKA were higher on hematopoietic progenitor cells in blood from PMF patients than from healthy controls, and in...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Alisertib: Phase III data

The open-label, international Phase III Lumiere trial in 163 evaluable patients with relapsed or refractory PTCL showed that twice-daily 50 mg oral alisertib for the first 7 days of a 21-day cycle led to an...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Alisertib: Development discontinued

Takeda discontinued development of alisertib to treat relapsed or refractory PTCL after a pre-specified interim analysis of an open-label, international Phase III trial showed that twice-daily oral alisertib for the first 7 days of a...
01:56 , May 14, 2015 |  BC Extra  |  Clinical News

Takeda discontinues alisertib trial

Takeda Pharmaceutical Co Ltd. (Tokyo:4502) discontinued a Phase III trial of alisertib ( MLN8237 ) to treat relapsed or refractory peripheral T cell lymphoma (PTCL). Takeda said an interim analysis showed the trial was unlikely...